The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study

Creative Commons License

GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., ...Daha Fazla

TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.52, sa.5, ss.1551-1558, 2022 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 52 Sayı: 5
  • Basım Tarihi: 2022
  • Doi Numarası: 10.55730/1300-0144.5495
  • Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.1551-1558
  • Anahtar Kelimeler: Fulvestrant, hormone-positive, breast cancer, real-life, FALCON study, 500 MG, POSTMENOPAUSAL WOMEN, METAANALYSIS, TRASTUZUMAB, LETROZOLE, THERAPY
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background/aim: We aimed to evaluate the efficacy of fulvestrant and its affecting clinical factors, including the optimal sequencing of fulvestrant and chemotherapy in a real-life cohort.